H. Lundbeck A/S/DKr HLUN B

1D1W1MYTD1Y5YMAX

About H. Lundbeck A/S

H. Lundbeck A/S is a Danish pharmaceutical company specializing in the research, development, and marketing of products for the treatment of brain diseases. The company focuses on areas such as depression, schizophrenia, Alzheimer's disease, and Parkinson's disease. Founded in 1915, Lundbeck is headquartered in Valby, Denmark, and has a significant global presence with facilities across Europe, North America, and Asia. Lundbeck's strategic positioning is underscored by its dedicated emphasis on central nervous system disorders, supported by a robust pipeline of research and development projects. The company places a strong emphasis on scientific and clinical excellence, aiming to deliver innovative therapies to improve patient outcomes.
Ticker
DKr HLUN B
Sector
Health
Primary listing
CSE
Employees
5,000
Headquarters
Valby, Denmark
Website
www.lundbeck.com

H. Lundbeck A/S Metrics

BasicAdvanced
kr 41B
10.55
kr 3.97
0.26
kr 1.15
2.75%

Bulls say / Bears say

Lundbeck delivered strong H1 2026 momentum: revenue rose 16% at constant exchange rates, led by Vyepti and Rexulti, while adjusted EBITDA increased 19%. Management also raised its full-year revenue and EBITDA growth guidance in May and said it was tracking towards the upper end in August. (PR Newswire, Cision News)
The pipeline is reaching important late-stage milestones. Bexicaserin has completed enrolment in its Phase III DEEp OCEAN trial and carries US and Chinese Breakthrough Therapy designations, while amlenetug has completed recruitment in its Phase III MASCOT trial for a disease with no approved treatment. (PR Newswire, Inderes)
Lundbeck may have room to scale beyond its current portfolio. Jefferies says the company is moving into a multi-year scaling phase, with plans to expand Vyepti globally and roughly EUR 2–3 billion of financial capacity for targeted business development as leverage is reduced. (MedWatch)
The reported H1 strength is partly flattered by a planned DKK 470 million inventory build linked to the partner-market transition, while underlying growth was 13% at constant exchange rates. Growth is also concentrated in Vyepti and Rexulti, increasing the importance of a small number of products. (PR Newswire)
Generic competition for Abilify Maintena is expected to begin affecting sales in the second half of 2026, initially in Australia and Canada. This could erode an established revenue stream before newer pipeline medicines reach the market. (Reuters)
The pipeline remains a timing and execution risk rather than a proven earnings stream. Bexicaserin has only reached completion of trial randomisation, while amlenetug's Phase III headline results are not expected until Q3 2027, leaving current brands exposed if studies are delayed or fail. (PR Newswire, MedWatch)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.

Funds containing H. Lundbeck A/S

AllUSDEURGBP
Funds
Fund name
Fund size
DKr HLUN B weighting
iShares Healthcare Innovation$HEAL
$1.4B0.20%
iShares Healthcare Innovation€2B78
€1.2B0.20%
iShares Healthcare Innovation£DRDR
£1B0.20%
iShares Ageing Population€AGED
€822M0.16%
Xtrackers MSCI Europe Small Cap€DX2J
€3.2B0.12%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.